- Home
- SGLY vs MBRX Comparison
SGLY vs MBRX Comparison
Compare SGLY & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- MBRX
- Stock Information
- Founded
- SGLY 2001
- MBRX 2015
- Country
- SGLY United States
- MBRX United States
- Employees
- SGLY N/A
- MBRX N/A
- Industry
- SGLY
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGLY
- MBRX Health Care
- Exchange
- SGLY Nasdaq
- MBRX Nasdaq
- Market Cap
- SGLY 5.8M
- MBRX 7.0M
- IPO Year
- SGLY 2008
- MBRX 2016
- Fundamental
- Price
- SGLY $1.55
- MBRX $1.67
- Analyst Decision
- SGLY
- MBRX Strong Buy
- Analyst Count
- SGLY 0
- MBRX 3
- Target Price
- SGLY N/A
- MBRX $31.00
- AVG Volume (30 Days)
- SGLY 14.2K
- MBRX 49.2K
- Earning Date
- SGLY 11-14-2024
- MBRX 11-08-2024
- Dividend Yield
- SGLY N/A
- MBRX N/A
- EPS Growth
- SGLY N/A
- MBRX N/A
- EPS
- SGLY N/A
- MBRX N/A
- Revenue
- SGLY $2,742,157.00
- MBRX N/A
- Revenue This Year
- SGLY N/A
- MBRX N/A
- Revenue Next Year
- SGLY N/A
- MBRX N/A
- P/E Ratio
- SGLY N/A
- MBRX N/A
- Revenue Growth
- SGLY N/A
- MBRX N/A
- 52 Week Low
- SGLY $1.27
- MBRX $0.40
- 52 Week High
- SGLY $7.65
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- SGLY 43.10
- MBRX 30.60
- Support Level
- SGLY $1.58
- MBRX $1.81
- Resistance Level
- SGLY $1.71
- MBRX $3.10
- Average True Range (ATR)
- SGLY 0.09
- MBRX 0.25
- MACD
- SGLY -0.00
- MBRX -0.10
- Stochastic Oscillator
- SGLY 35.71
- MBRX 0.00
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.